EBV-MS
Targeting the Epstein-Barr virus to treat and prevent MS (EBV-MS) is a ground-breaking Horizon Europe-funded research project with leading universities and hospitals in Europe and the USA. We are aiming to unveil the role of the Epstein-Barr virus (EBV) in the onset and progression of the Multiple Sclerosis (MS) disease.
The aim of the project, led by the University of Bergen, is to understand why only a few EBV infected people develop MS, and define the underlying mechanism of this process. The project will also investigate whether targeting the EBV infection with antiviral treatments can improve the disease course or stop disease progression.
Project managers:
Kjell-Morten Myhr, Project Manager, e-mail: kjell-morten.myhr@uib.no, tel: +47 55976031 / +47 41447868
Øivind F. Grytten Torkildsen, Deputy Project Coordinator, e-mail: Oivind.Torkildsen@uib.no
![(From left to right): Professor Øivind Torkildsen [credit: Eivind Senneset], Silje Tufta [credit Silje Tufta], and Dr. Sam Anandhan [credit: Spiros Kotopoulis]](https://www.uib.no/sites/w3.uib.no/files/styles/wide_thumbnail/public/media/bilde1_33.png?itok=Gjv-6x7N)
This project has received funding from the European Union’s Horizon Europe Research and Innovation Actions under grant no. 101136991 (EBV-MS). Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.